Cargando…
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome. Driven by the unmet need to develop better therapies for KMT2A-rearranged leukemia, we previously discovered that the novel anti-...
Autores principales: | Xiao, Lin, Karsa, Mawar, Ronca, Emma, Bongers, Angelika, Kosciolek, Angelika, El-Ayoubi, Ali, Revalde, Jezrael L., Seneviratne, Janith A., Cheung, Belamy B., Cheung, Laurence C., Kotecha, Rishi S., Newbold, Andrea, Bjelosevic, Stefan, Arndt, Greg M., Lock, Richard B., Johnstone, Ricky W., Gudkov, Andrei V., Gurova, Katerina V., Haber, Michelle, Norris, Murray D., Henderson, Michelle J., Somers, Klaartje |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168530/ https://www.ncbi.nlm.nih.gov/pubmed/35677155 http://dx.doi.org/10.3389/fonc.2022.863329 |
Ejemplares similares
-
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
por: Fetisov, Timur I., et al.
Publicado: (2023) -
Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018) -
Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
por: Dallavalle, Sabrina, et al.
Publicado: (2021) -
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
por: Burkhart, Catherine, et al.
Publicado: (2014) -
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)